Brief: Mirati Announces IND Clearance By U.S. FDA
19/01/2023 22:01
Jan 19 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI ANNOUNCES IND CLEARANCE BY U.S. FDA ENABLING PHASE
1
INITIATION FOR FIRST-IN-CLASS ORAL KRASG12D SELECTIVE INHIBITOR,
MRTX1133
* MIRATI THERAPEUTICS INC - PHASE 1/2 CLINICAL TRIAL WILL
LAUNCH
IN EARLY 2023
Source text for Eikon: ID:nPn52ydXpa
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)